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Abstract
ObjectiveTranssphenoidal pituitary surgery (TS) is the
primary treatment of choice for patients with acromegaly.
Macroadenomas (>1 cm) are more difficult to resect than
microadenomas (remission rate ± 50% compared to ± 90%).
Besides the conventional microscopic TS, the more recently
introduced endoscopic technique is nowadays frequently
used. However, no large series reporting on its results have
yet been published. We evaluated the outcome of endo-
scopic TS in 40 patients with a growth hormone (GH)-
secreting macroadenoma treated in our hospital between
1998 and 2007.
Methods Medical records were retrospectively reviewed.
Remission was defined as disappearance of clinical symp-
toms of acromegaly, normal serum insulin-like growth
factor-1 levels (≤2 SD) and serum GH levels suppressed
to <2 mU/l after an oral glucose tolerance test within the
first 4 months after TS.
Results In four patients TS aimed at debulking of the
tumour. In the remaining 36 patients, remission was
achieved in 20 patients. In the first 5 years remission was
achieved in 6 out of 18 patients (33%) compared to 14 out
of 22 patients (63%) in the following 5 years (p=0.06).
Thirteen patients had a mild perioperative complication.
Before TS 15 patients received hormonal substitution
therapy compared to 12 patients (33%) after TS.
Conclusion Endoscopic TS is a good primary therapeutic
option for patients with a GH-secreting macroadenoma,
resulting in a remission rate of up to 63% in experienced
hands. This technique can potentially improve the outcome
of TS in these patients.
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Introduction
Untreated acromegaly causes significant morbidity, and is
associated with a two- to threefold increase in mortality.
When acromegaly is treated successfully and “safe” growth
hormone (GH) and insulin growth factor-1 (IGF-1) values
are achieved, the mortality rate normalises [32]. Therefore,
appropriate treatment of acromegaly is crucial. However,
symptoms and signs of acromegaly develop insidiously,
and there is often a delay in diagnosis for up to 10 years.
Therefore, approximately 70% of GH-secreting adenomas
are ≥1 cm (macroadenomas) at the time acromegaly is
diagnosed [32].
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(TS) is the treatment of choice for acromegaly [28, 31],
potentially rapidly restoring normal physiology by a single
intervention. Macroadenomas, however, are difficult to
remove by TS, especially when invasive. This may explain
the relatively low remission rate of about 50% reported
after TS in macroadenomas, whereas remission rates up to
90% are achieved by TS in microadenomas (<1 cm) [34].
Since more recently developed medical therapies achieve
good results in controlling acromegaly, some authors have
recommended medical therapy as a primary treatment
option instead of TS for patients with a GH-secreting
macroadenoma that does not cause mass effects [13, 25].
Nowadays, the endoscopic technique of TS is increas-
ingly used by many neurosurgeons instead of the conven-
tional microscopic technique. This technique, offering a
panoramic wide angle view with increased illumination,
was first developed in the 1990s. Different angles can be
used, making it possible to effectively reach supra- and
parasellar portions of the lesion and work around the corner
[10, 14]. Due to these advantages, it has been suggested
that the endoscopic technique may be preferable to the
conventional technique, especially in patients with invasive
macroadenomas [14, 28, 39]. However, due to the recent
introduction of this technique, no large series reporting on
the results of endoscopic TS in acromegaly have yet been
published.
To gain insight in the role of endoscopic TS as a primary
treatment option for patients with GH-secreting macro-
adenomas, we evaluated the results of endoscopic TS in 40
consecutive patients with a GH-secreting macroadenoma
treated in our hospital between 1998 and 2007.
Patients and methods
Patients
Between 1998 and 2007, 40 patients with acromegaly and a
macroadenoma on a preoperative magnetic resonance
imaging (MRI) scan underwent endoscopic TS in our
centre. The medical records of these patients (19 males
and 21 females, Table 1) were retrospectively reviewed.
Age at time of TS was 47.4±11.4 (mean±SD) years and
BMI was 29.0±4.9 kg/m
2. We collected data on preoper-
ative as well as early postoperative evaluation, complica-
tions that occurred during TS or in the early postoperative
period, and data on the follow-up of these patients.
Preoperative evaluation and perioperative treatment
The initial diagnosis of acromegaly was based on clinical
grounds and biochemical tests, including assessment of
serum GH levels (basal and after oral administration of
glucose) and serum IGF-1 levels. Furthermore, the thyro-
tropic, gonadotropic and pituitary-adrenal axes were
assessed, as well as the prolactin blood level. Preoperative
pituitary imaging by MRI was performed in all patients.
Long-acting somatostatin analogues (SA) were given
preoperatively in 34 patients for a median period of
7 months (range 1–28), 1 patient received 10 mg/4 weeks,
20 patients received 20 mg/4 weeks and 13 patients
received 30 mg/4 weeks.
One hour before surgery, administration of glucocorti-
coids (prednisolone, 25 mg i.v. every 8 h) was started. Two
days after surgery glucocorticoid administration was
changed from i.v. to oral, and the dose was tapered rapidly.
Surgical technique
The endoscopic technique of TS was introduced in our
hospital in 1994 and first used for acromegaly in 1998.
From 1998 onward practically all TSs (n=365) were
performed endoscopically. The surgeries were exclusively
performed by two neurosurgeons. The technique is very
similar to the technique that Jho et al. and Cappabianca et
al. have described previously [7, 8, 21, 22]. However, a
binostril transsphenoidal approach to the sella turcica was
used, during which the endoscope was handheld.
For the endoscopic transnasal TS, 0º and 30° rigid
endoscopes with a lens diameter of 4 mm with a separate
shaft were used, which allow easy and comfortable holding,
while offering a suction-irrigation-system for cleaning the
lens (Karl Storz GmbH, Tuttlingen, Germany). The instru-
ments used are principally the same as used with the
microsurgical technique. Because an adenoma was visible
on preoperative MRI, a selective adenomectomy was
performed in all patients.
Postoperative evaluation
A complication of TS was defined as any event occurring
during or after TS that required treatment. As intraoperative
cerebrospinal fluid (CSF) leakage is inherent to the surgical
procedure and is closed during TS with a fat graft, it was
not regarded as a complication, whereas postoperative CSF
leakage was considered a complication.
On the 7th day postoperatively, at least 48 h after the
last dose of glucocorticoids, early biochemical evaluation
was carried out by measuring the serum concentrations of
IGF-1, fasting cortisol, adrenocorticotropic hormone
(ACTH), thyrotropin (TSH), free thyroxine (FT4), gona-
dotropines (LH and FSH), testosterone, estradiol and
prolactin.
Patients were re-evaluated every 2 to 4 weeks during
the first 3 months after surgery. Serum GH and IGF-1
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surgery a new MRI of the pituitary was performed to
check for tumour remnants. An oral glucose tolerance
test (OGTT; 100 g of glucose [36]) was performed if the
IGF-1 level had normalised or was marginally elevated.
Thereafter patients who were in remission were evaluated at
least once a year or earlier in case of clinical suspicion of a
relapse.
Criteria for remission and relapse
Remission was defined as disappearance of clinical
symptoms of active GH hypersecretion with in addition
normal serum IGF-1 levels (≤mean+2 standard devia-
tions for age) and suppression of serum GH levels to
<2 mU/l during OGTT within the first 4 months after
surgery [19, 20].
Relapse was defined as development of clinical signs of
active GH hypersecretion with elevated serum IGF-1 levels
(>mean+2 standard deviations for age) and serum GH
levels ≥2 mU/l during OGTT [19, 20].
Imaging
All preoperative and postoperative MRI scans were evalu-
ated by the same neurosurgeon to prevent bias. Maximal
diameter of the adenoma was defined as the largest distance
that could be measured in any direction of the adenoma.
Invasion was defined as suspected growth of the adenoma
beyond the sella into the cavernous sinus or the sphenoid
sinus.
Analysis of factors influencing outcome and statistics
Data were analysed using SPSS 16.0. Characteristics of
patients operated on in the first and second 5 years were
compared using unpaired T-test and Pearson’s chi-square
test. The influence of various factors on the chance to
achieve remission by TS was analysed by binary logistic
regression. The factors analysed were: date of operation (as
a surrogate measure for experience of the neurosurgeons),
age, gender, the level of preoperative IGF-1 and GH, the
diameter of the adenoma on preoperative MRI, evidence of
invasion on the preoperative MRI, occurrence of perioper-
ative complications and the need for hormonal substitution
therapy after TS. The influence of dichotomous variables
(gender, substitution therapy before TS, evidence of
invasion on the preoperative MRI, TS in the first or second
5 years, occurrence of perioperative complications and the
need for hormonal substitution therapy after TS) on the
chance of remission were also analysed using Pearson’s
chi-square test. Statistical significance was defined as
p=<0.05 (two-sided).
Results
Remission rates after TS
The results of endoscopic TS in the 40 patients with a GH-
secreting macroadenoma are shown in Fig. 1. The individ-
ual data per patient are presented in Table 1. Histological
investigation of the removed tissue showed evidence of a
GH-producing adenoma in all cases. The overall remission
rate in our series is 50%. However, four patients (patients
21, 30, 33 and 34, Table 1) had an invasive adenoma of
more than 30 mm in diameter and suffered from local mass
effects. The intention of the TS in these patients was to
debulk the adenoma, as it was appreciated that cure could
not be achieved by TS. In the remaining 36 patients, in
whom the intent was cure, remission was achieved in 20
patients. In this group the remission percentage thus was
56%. Median follow-up was 56 months (range 6–126).
Recently, two patients (patients 12 and 35) developed a
mild relapse. Patient 12 is now being treated with
octreotide, while the relapse of patient 35 was very mild
and no treatment had yet been initiated.
The date of TS significantly influenced the chance of
remission after TS. If a patient was operated on at a later
date, the chance of achieving remission after TS was higher
(p=0.04). If the results of TS during the first 5-year interval
after the introduction of the endoscopic technique are
compared with the second 5-year interval, remission was
achieved in 6 out of 18 patients (33%) during the first
5 years, whereas in the next 5 years, 14 of 22 patients
(63%) were in remission after TS (p=0.06). However, the
four patients who only underwent debulking were all
operated on in the last 5 years. If these patients are
excluded, the remission rate achieved in the last 5 years is
77%, which is significantly better than the remission rate
over the first 5 years (p=0.01). Table 2 shows that baseline
characteristics of patients operated on during the first
5 years do not significantly differ with baseline character-
istics of patients operated on during the last 5 years, except
for preoperative IGF-1 levels, which were significantly
higher in the second group. This does not change if the four
patients who underwent debulking are excluded.
Therewere no statistically significantdifferences between
the patients who underwent successful or unsuccessful TS
with respect to age, gender, occurrence of perioperative
complications, preoperative IGF-1 levels or need for
hormonal substitution therapy after TS. There was a trend
that if the diameter of the adenoma was larger, the chance to
achieve remission was smaller (p=0.06 in all patients);
however if the four patients who underwent only debulking
were excluded, this trend was no longer present (p=0.56).
Eight of 19 patients (42%) with evidence of invasion on
preoperative MRI, and 12 of 21 patients (57%) without
Acta Neurochir (2011) 153:1391–1399 1393Table 1 Results of endoscopic transsphenoidal pituitary surgery in patients with acromegaly (1998–2007)
Patient number,
gender, age (years)
Preoperative
octreo-tide
MRI
(mm)
Invasion on
preoperative MRI
Year of
TS
Postoperative
IGF-1
Postoperative
oGTT
TS
result
Additional
therapy
Last IGF-1 Follow-up
(months)
nmol/l SD nmol/l SD
1. f, 52 Y 20 Sc r 1998 50.3 >2 - F RT+cab 19.0 1 127
2. m, 43 N 25 - 1999 24.0 1 38 F Octr 32.8 >2 38
3. f, 27 N 18 Sc r 2000 92.7 >2 9 F GK 10.6 -2 109
4. m, 40 Y 10 - 2000 23.1 1 <2 R - 12.9 -1 106
5. f, 24 Y 17 - 2000 77.0 >2 - F Octr+cab 41.0 >2 78
6. f, 59 Y 20 Ssphen,sc l 2001 64.5 >2 - F TS, RT+peg 15.6 0 76
7. f, 54 N 11 Sc l 2001 62.8 >2 - F RT+octr 23.5 1 73
8. m, 39 N 14 - 2001 73.6 >2 - F RT+octr, cab 28.1 2 68
9. m, 49 Y 43 Ssphen, sc l+r 2001 60.5 >2 - F TS+octr, cab 21.6 1 91
10. f, 50 Y 12 - 2001 10.2 -2 <2 R - 15.4 0 74
11. f, 49 Y 13 - 2001 38.4 >2 - F Octr 14.0 0 91
12. m, 37 Y 20 - 2001 28.3 1 <2 R Octr 15.6 0 87
a
13. m, 44 Y 10 Sc r 2001 83.6 >2 - F GK+octr, peg 27.9 2 86
14. f, 34 Y 16 - 2002 10.5 -2 <2 R - 11.4 -2 70
15. f, 55 Y 18 - 2002 30.9 >2 3 F Octr 9.8 -2 86
16. f, 56 Y 11 Sc r 2002 12.7 -1 <2 R - 13.6 0 79
17. m, 56 Y 14 - 2002 16.8 0 <2 R - 15.2 0 77
18. m, 64 Y 12 - 2002 18.0 1 2 F Octr 18.3 1 57
19. f, 66 Y 16 Ssphen, sc r 2003 27.1 2 <2 R - 25.0 2 65
20. f, 45 Y 30 Sc l 2003 24.7 1 <2 R - 29.0 2 48
21. m, 35 Y 39 Ssphen 2003 66.3 >2 - F Octr 14.1 -1 69
22. f, 56 Y 15 Sc r 2003 15.3 0 <2 R - 16.5 0 47
23. f, 41 Y 15 - 2003 28.0 1 <2 R - 22.7 1 66
24. m, 54 Y 13 - 2004 19.8 1 <2 R - 16.6 0 44
25. f, 43 Y 11 - 2004 29.5 2 <2 R - 22.8 1 43
26. m, 48 N 12 - 2005 35.8 >2 - F Octr 23.6 1 31
27. f, 29 Y 10 Sc l 2005 25.6 1 <2 R - 23.5 1 37
28. f, 51 Y 13 - 2005 11.7 -1 <2 R - 15.6 0 49
29. m, 64 Y 14 Sc r 2005 30.0 >2 - F Cab 21.4 1 36
30. m, 68 Y 30 Sc l+r, ssphen 2005 31.5 >2 - F Octr 16.8 1 30
31. m, 46 Y 21 - 2005 43.1 >2 <2 F - 36.2 >2 32
32. m, 45 N 15 - 2005 46.0 >2 <2 F - 31.3 >2 38
33. m, 35 Y 42 Sc l+r 2005 163.8 >2 595 F RT+octr, cab 56.9 >2 33
34. f, 28 Y 45 Sc l+r 2006 98.7 >2 - F RT+octr 33.3 >2 15
35. f, 67 Y 11 - 2006 21.5 1 <2 R - 27.4 >2 31
a
36. m, 40 Y 21 Sc r 2007 22.9 0 <2 R - 21.3 1 14
37. m, 62 Y 20 - 2007 18.4 1 <2 R - 18.4 1 6
38. f, 41 Y 24 Sc re 2007 31.7 2 <2 R - 12.0 -1 15
39. f, 46 Y 18 - 2007 16.2 0 <2 R - 21.3 1 8
40. m, 54 Y 27 Sc r 2007 26.6 2 <2 R - 26.6 2 6
f: female; m: male; preoperative octreotide Y: treated with octreotide before surgery; preoperative octreotide N: not treated with octreotide before
surgery; MRI: magnetic resonance imaging results given as maximal diameter of the visualised tumour in mm; sc r: cavernous sinus right; sc l:
cavernous sinus left; ssphen: shenoid sinus; ssphen: sphenoid sinus; TS: transsphenoidal surgery; IGF-1 nmol/l: value of insulin-like growth
factor-1; IGF-1 SD: standard deviation of insulin-like growth factor-1 compared to normal values in people of the same age and sex; oGTT:
minimal value of growth hormone achieved during the postoperative oral glucose tolerance test; GTT -: no oral glucose tolerance test performed
after surgery; TS result R: remission; TS result F: failure; RT: conventional radiotherapy; octr: octreotide; cab: cabergoline; GK: gamma knife
radiosurgery; peg: pegvisomant;
a: relapse at last follow-up
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patients in whom the intention of the TS was to debulk the
adenoma were not taken into account, the remission rate in
patients with suspected invasion was 53%, indicating that in
this study invasion did not significantly influence the chance
to achieve remission (p=0.82).
Additional treatment and benefits of TS in patients
with persistent acromegaly after TS
Although remission was not achieved via TS in 20 patients,
the maximal diameter of the adenoma was reduced from a
median of 18 mm (range 10–45) on the preoperative MRI
to a median of 7 mm (range 0–35) on the MRI performed 4
months after surgery. The adenoma was reduced in size in
all patients, and in six patients no residual adenoma was
visible on the postoperative MRI. In three patients (patients
11, 15 and 18), normal IGF-1 levels could be achieved with
a dose of octreotide that was the same or even lower than
the dose prescribed before the operation and that had been
insufficient to suppress IGF-1 to normal levels before TS.
Figure 1 shows how the 20 patients with persisting
acromegaly after TS were treated. A second TS was
attempted in two patients but failed to result in cure. Of the
eight patients receiving additional conventional radiothera-
py, none is presently in remission and all are still receiving
medical treatment to control the acromegaly. Radiosurgery
(γ-knife) was performed in two patients and resulted in
remissioninoneofthem.Of theremaining patients notcured
by the TS, all patients except patient 32 and 33 were
exclusively treated with medication. Patient 32 and 33 did
not receive any further treatment. In patient 32 the IGF-1
level was only slightly elevated with no symptoms of active
acromegaly, GH was suppressed to <2 mU/l after OGTT,and
the mean GH values are below 6.5 mU/l. Patient 33 refused
to be tested or treated further after TS because the symptoms
of acromegaly had disappeared.
Complications of TS and influence of TS on deficiencies
of pituitary hormones
Only mild complications occurred in our series. Fourteen
patients developed a very mild transient diabetes insipidus
(DI) for a maximum of 2 to 3 days. This was not regarded
as a complication. Only one patient (patient 33) had a more
severe transient DI. Five patients, of whom two had had mild
transient DI early after the operation, were treated with fluid
restriction when they developed a mild hyponatremia
Table 2 Comparison of baseline characteristics of the patients operated on during the first 5 years and the patients operated on during the second
5 years
First 5 years (n=18) Second 5 years (n=22) Significance
Gender (% male) 8 (44%) 11 (50%) p=0.76
Age (years) 46.2 (±11.0) 48.4 (±11.9) p=0.56
BMI (kg/m
2) 29.8 (±4.4) 26.6 (±5.3) p=0.32
Preoperative medication 13 (72%) 20 (91%) p=0.12
Adenoma diameter (cm) 16.9 (±7.8) 20.9 (10.4) p=0.18
Invasion on preoperative MRI 7 (39%) 12 (54%) p=0.32
Preoperative IGF-1 value (nmol/l) 93.3 (±23.5) 116.6 (±36.9) p=0.03
Data are expressed as means and standard deviations in case of continuous variables and as exact numbers and percentages in case of nominal or
ordinal variables. BMI: Body mass index; IGF-1: insulin-like growth factor-1; MRI: magnetic resonance imaging
Fig. 1 Results of endoscopic
pituitary surgery in patients
with a growth hormone
secreting macroadenoma
(1998–2007)
Acta Neurochir (2011) 153:1391–1399 1395because of inappropriate ADH secretion. Four patients had
mild epistaxis, controlled with nasal tampons. Three patients
had cerebrospinal fluid (CSF) leakage postoperatively. They
were treated successfully with an external lumbar drain.
Fifteen patients (38%) already received substitution
therapy for deficiency of one or more hormones before
TS. After TS 33% of all patients receive long-term
hormonal substitution. Twenty percent of the patients
receive substitution with levothyroxine, 12.5% receive
androgens, 12.5% receive glucocorticoids, 2.5% receive
GH therapy and 2.5% receive desmopressin (Table 3).
Discussion
In this study we report on the results of endoscopic TS in
40 consecutive patients with acromegaly and a pituitary
macroadenoma on preoperative MRI, operated on in our
hospital between 1998 and 2007. Although some results of
endoscopic TS in small numbers of patients with acromeg-
aly have been mentioned in large series of patients with
different pituitary tumours [6, 11, 26, 42], no series
focussing on the results of endoscopic TS in patients with
acromegaly have yet been published. All previous pub-
lished series on results of TS in patients with GH-secreting
macroadenomas used the conventional technique of TS.
Remission rates after conventional TS reported in these
larger series of patients with GH-secreting macroadenomas
(including giant macroadenoma) vary widely, from 15 to
71% (Table 4)[ 1, 2, 4, 15, 18, 23, 29, 34, 40, 41, 43, 45].
The overall remission rate of 50% in this study is in
concordance with these results. However, not all series have
used the same criteria to describe remission. The studies
that used the criteria for remission formulated by Giustina
et al. in 2000 [19, 20], as we did in our series, reported
remission rates in patients with macroadenomas of maxi-
mally 50%. Therefore, the remission rate of 50% reported
in our series is comparable to the best previously published
remission rates achieved in patients operated on by the
conventional microscopic method of TS.
However, the remission rate of 63% (or 77% if the
patients who underwent debulking are excluded) we
achieved in the last 5 years, compared to a remission rate
of 33% in the first 5 years, is very promising for the future.
The characteristics of patients operated on in the first
5 years and second 5 years were comparable (Table 2). The
only significant difference was that the patients operated
upon in the second 5 years had a significantly higher IGF-1
level. Therefore, we believe that the higher remission rate
achieved in the last 5 years is not biased by patients on
whom it was easier to operate. So, it is more likely that the
large difference between the remission rate achieved in the
Levothyroxine
substitution
Androgen
substitution
Glucocorticoid
substitution
GH
substitution
Desmopressin
substitution
Total
Discontinued after TS 5 5 1 11
Started after TS 4 2 2 1 1 10
Continued after TS 4 3 3 10
Table 3 Influence of transsphe-
noidal surgery on substitution
therapy in 40 patients with
acromegaly caused by a
macroadenoma
TS: transsphenoidal surgery,
GH: growth hormone.
Table 4 Review of the criteria to define remission of acromegaly and remission percentages in macroadenomas reported in the most recently
published series (1997–2005)
Author N Criteria of remission Remission %
van Lindert et al. [45] 40 GH <2 ng/ml after OGTT, IGF1 N 55
Abosch et al. [2] 254 Basal GH <5 ng/ml 71
Swearingen et al. [41] 129 GH <2 ng/ml after OGTT or IGF1 N or basal GH <2.5 ng/ml 48
Gittoes et al. [18] 45 GH <2 mU/l after OGTT or basal GH <5 mU/l 51
Laws et al. [29]5 1 G H ≤1 ng/ml after OGTT or IGF1 N or basal GH ≤2.5 ng/ml 51
Kaltsas et al. [23] 50 Basal GH <2.5 ng/ml, IGF1 N 26
Abe and Ludecke [1] 126 Basal GH <2.5 ng/ml, IGF1 N 68
Shimon et al. [40] 44 GH <2 ng/ml basal or after OGTT, IGF1 N 64
Beauregard et al. [4]7 7G H ≤1 ng/ml after OGTT or IGF1 N or basal GH ≤2.5 ng/ml 49
Trepp et al. [43] 64 GH <1 ng/ml after OGTT or IGF1 N or basal GH <2.5 ng/ml 39
Erturk et al. [15]1 9 G H ≤2 ng/ml basal or after OGTT 15
Nomikos et al. [34] 364 GH <1 ng/ml after OGTT or IGF1 N or GH <2.5 ng/ml 50
N: number of patients included; GH: growth hormone; OGTT: oral glucose tolerance test; IGF1: insulin-like growth factor type 1
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endoscopic technique of TS can be explained by the
increasing experience of the two neurosurgeons who
performed all endoscopic TSs in our hospital. Strong
evidence exists that success rates of microscopic TS
critically depend on the skills and experience of the
neurosurgeon [3, 15, 18]. Our data indicate that this is no
different for endoscopic TS. This argues in favour of
concentrating endoscopic TS for acromegaly in a limited
number of experienced centres.
Previously published series on conventional microscopic
TS in patients with acromegaly and a macroadenoma found
that the chance of remission after TS could be predicted by
the suspected invasiveness of the macroadenoma on the
preoperative MRI scan [2, 4, 18]. However, in this study,
although we observed a non-significant trend towards a
lower chance of successful TS if tumour invasion was
suspected, remission was still achieved in 42% of patients
with suspected invasion. This may be explained by the fact
that the endoscopic technique enables the use of different
angles to operate, making it possible to reach suprasellar
and parasellar portions of the lesion effectively [10, 14]. If
this is the case, the endoscopic technique might be
preferable in case of invasive macroadenomas.
Due to the good results that have been achieved by
medical therapy in patients with acromegaly and the
relatively low remission rates after TS for patients with a
GH-secreting macroadenoma, some authors have recom-
mended medical therapy as a primary treatment option
instead of TS for patients with a GH-secreting macro-
adenoma not causing mass effects [13, 25, 39]. Nowadays
long-acting somastatin analogues (SA) have the potential to
normalise IGF-1 levels in two thirds of patients, addition-
ally controlling tumour size [17]. The more recently
developed GH receptor antagonist pegvisomant can nor-
malise IGF-1 in up to 97% of patients [44]. Furthermore,
studies on combination therapies with SA and pegvisomant
or SA and dopamine agonists have shown that combination
therapy may be successful when monotherapy has failed
[16, 33, 38]. Although medical treatment can result in long-
term remission, it cannot cure acromegaly. Moreover,
pegvisomant, which is effective by preventing GH action
in the target tissues (organs), lacks a direct effect on the
tumour to control long-term tumour growth. This might
limit its use as primary therapy for patients with macro-
adenomas until more long-term data on safety are available.
Last but not least, lifelong use of expensive medication is
required with the risk of serious side effects.
Studies have shown that surgical debulking can improve
control of acromegaly by SA [12, 24, 35]. So even if a
patient cannot be cured by TS, TS should still be
considered, especially if acromegaly cannot be controlled
by SA before TS. In this study TS reduced the size of the
adenoma in all patients who were not cured by TS and
improved the response to SA treatment in at least five of
these patients. Unfortunately, a preoperative IGF-1 value
during SA therapy was not available in all patients, so
possibly more patients benefited from the TS to control
their acromegaly.
Preoperative treatment with SA has been associated with
improved results of TS, especially in macroadenomas [1, 5,
9, 30]. This could possibly be explained by adenoma
shrinkage or a change in the consistency of the adenoma
[9]. However, most published studies have limitations.
They are retrospective, have poor remission rates or small
numbers of patients. Furthermore, other studies have not
confirmed this positive effect [27, 37]. A negative effect of
preoperative treatment with SA on the outcome of TS
results, however, has never been found. Therefore, and
because pretreatment with SA improves metabolic control,
we prescribed preoperative therapy with octreotide in all
but six patients. Of these six patients, none achieved
remission after TS. However, because of the small number
of patients who did not receive preoperative treatment and
the retrospective character of this study, it was not possible
to evaluate whether preoperative treatment had an effect on
the results of TS.
Thirteen patients in our study had a perioperative
complication. All complications were mild, and no serious
complications occurred. This is in concordance with the
incidence of complications associated with TS via the
microscopic technique [1, 2, 4, 15, 18, 23, 29, 34, 40, 41,
43, 45]. However, the endoscopic technique is probably
more comfortable for the patients as the nose septum is
almost left intact and usually no nasal packing is required
after surgery. Besides the four patients with mild epistaxis,
no rhinologic/local complications occurred, which seems to
be less than those reported with the conventional technique.
However, most patients that are operated upon via the
microscopic technique do not need nasal packaging, but
receive it because of a longstanding surgical habit.
In this series the number of hormonal deficiencies
caused by TS was equal to the number of deficiencies cured
by TS. All patients had a macroadenoma, which frequently
causes a hormonal deficiency by itself before surgery. If the
adenoma is selectively removed, normal pituitary function
can potentially be restored [45]. Therefore, in macro-
adenomas, the fear of creating new hormonal deficiencies
should probably not be a reason to restrain from TS.
Conclusion
Endoscopic TS is a treatment that should be considered as a
primary therapeutic option for patients with a GH-secreting
macroadenoma. In this series of patients operated on by
Acta Neurochir (2011) 153:1391–1399 1397experienced surgeons, it resulted in a remission rate of at
least 50%, with only mild complications. The relatively
high remission rate of 63% (or 77% excluding the patients
who underwent primary debulking) we achieved in the last
5 years indicates that operation results can improve further
if experience is gained. Because the endoscopic technique
enables the surgeon to use different angles, this technique
can potentially improve the outcome of TS in macro-
adenomas, especially in patients with invasive macro-
adenomas. However, a randomised clinical trial comparing
endoscopic and conventional TS in patients with a GH-
secreting macroadenoma is needed to determine the exact
pros and cons of both techniques.
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